MedTrace Logo

High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4

NCT00662220 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2014-07-14

No results posted yet for this study

Summary

Optimal ribavirin dosages are essential in achieving SVR (sustained virological response). Several studies have shown higher SVR rates in patients receiving higher doses of ribavirin. Therefore we propose a randomized controlled open label multicenter trial to investigate wether high (25-29mg/kg) dose ribavirin can improve outcome in patients in infected with hepatitis C virus genotype 1 or 4 compared to standard dose (12-15mg/kg).

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

ribavirin

25-29 mg/kg/day

DRUG

ribavirin

12-15 mg/kg/day

Sponsors & Collaborators

Principal Investigators

  • R J de Knegt, MD PhD · Erasmus Medical Center

  • J PH Drenth, MD PhD · St Radboud Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2013-06-30
Completion
2013-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00662220 on ClinicalTrials.gov